Women’s Health Therapeutics Market Expected To Trigger A Revenue Increase To USD 210.9 Billion By 2025:Key Participant Pfizer, Teva Pharmaceutical Industries Ltd

San Francisco, 23 October 2018 , The global Women’s Health Therapeutics Market size is expected to reach USD 210.9 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 8.8% over the forecast period. Entry of effective drugs, a rise in awareness about early diagnosis and treatment, along with prevalence of chronic diseases are among the key factors likely to drive the market during the forecast period.

The women’s health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications. In October 2016, Prelude Fertility, Inc. received USD 200 million from the Reproductive Biology Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing fertility services and treatment to people with delayed childbirth. Juneau Biosciences, LLC has deployed USD 35 million until 2017 towards development of molecular diagnostics and therapeutics for endometriosis (uterus) conditions.

In January 2018, Melinta Therapeutics, Inc. acquired The Medicines Company’s infectious diseases business. This acquisition would help to the former expand its portfolio by offering life-saving treatment options. In November 2017, Biocon launched KRABEVA, a biosimilar used for the treatment of metastatic colorectal, cervical, ovarian, and brain cancer. Increasing investments by top market players are anticipated to propel the global market over the forecast period.

There is significant unmet need associated with treatment options for female sexual dysfunction. Currently, there are no Food and Drug Administration (FDA)-approved drugs for the treatment of female sexual dysfunction and many promising molecules are in late stage of development phase. Some of these molecules include LibiGel by BioSante Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II of clinical trials respectively in U.S.

Full Research Report On Women’s Health Therapeutics Market Analysis:
www.grandviewresearch.com/industry-analysis/womens-health-therapeutics-market

Further key findings from the report suggest:

·         By type, infection accounted for the largest market share in 2017 and is expected to maintain its dominance during the forecast period due to rising drug approvals, availability of diagnostic tests and treatments, and high incidence of infectious diseases

·         Ovarian cancer is anticipated to be the fastest-growing sub-segment of oncology during the forecast period due to high prevalence of ovarian cancer and approval of new and improved drugs

·         North America is expected to maintain its dominance in the coming years due to high awareness about women’s health, increase in number of advanced diagnostic and treatment methods, mergers and acquisitions by market players, and rise in infections and cancer cases

·         Asia Pacific is likely to witness significant growth over the next decade due to improving healthcare facilities, increase in commercialization and approval of products, and investment by market players

·         Some of the key players in women’s health therapeutics market are Bayer AG, Merck & Co., Pfizer, Teva Pharmaceutical Industries Ltd, AstraZeneca, Bristol-Myers Squibb (BMS) Company, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and Sanofi.

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global women’s health therapeutics market based on type and region:

Women’s Health Therapeutics Type Outlook (Revenue, USD Million, 2014 - 2025)

·         Infection

·         Pregnancy

·         Oncology

o    Cervical Cancer

o    Ovarian Cancer

o    Uterine Cancer

o    Vaginal & Vulvar Cancer

Women’s Health Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    U.K.

o    France

o    Spain

o    Italy

·         Asia Pacific

o    China

o    Japan

o    India

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-womens-health-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Biosensors Market Is Anticipated to Attain Around USD 21.2 Billion By 2020:Key Participant AZUR Environmental

According to a report published by Grand View Research, Inc.; the Biosensors Market is expected to reach a valuation of around USD 21.2 billion by 2020.

Increasing prevalence of diabetic population base, growing demand for miniature diagnostic devices, technological innovation can propel the market during the forecast period (2012 to 2020).

Biosensors find wide range on medical applications. It can be used to measure blood metabolites such lactate, creatinine, urea, and glucose. These devices can be used for early detection of diabetes and cardiovascular diseases. Rapid technological advancements are expected to boost the market growth over the forecast period. For instance, revolutionary advancements of optical quantum dots is likely to provide new opportunities in biopharmaceutical development, vaccine development, and proteomic analysis. In addition, development of nanoparticle based electrochemical biosensors can also expected to drive the market growth. Moreover, additionally, increasing government efforts for development of genomics and proteomics are projected to boost the market. For instance, National Information and Communication Technology Australia (NICTA) is likely to increase research on networks, data mining, and embedded systems to be used in this field.

Full Research Report On Biosensors Market Analysis: www.grandviewresearch.com/industry-analysis/biosensors-market

Worldwide biosensors market can be segmented on the basis of type, application, end-user, technology, and region. Based on type, the market can be categorized into electrochemical, thermal, piezoelectric, and optical.

As per end-user, the market can be bifurcated into home healthcare diagnostics, PoC testing, food industry, research laboratories, and security and bio-defense.

In 2013, the electrochemical biosensors estimated for major market share due to increasing application of analysis and quantification in biological and biochemical processes.

Based on application, the market can be classified into medical, the market can be categorized into food toxicity, agriculture, bioreactor, environment, and others. In 2013, the medical segment acquired the largest market share around 66%. These devices are considered as an important tool for early detection and monitoring of cancers and diabetes.

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/medical-devices

The food toxicity segment is expected to show high growth due to increasing pressure from regulatory bodies associated to the hygiene standards of the food items for detecting allergens, pesticides, and pathogens in the food products.

On the basis of technology, the market can be split into thermal, electrochemical, piezoelectric, and optical.

Geographically, the market can be divided into North America, Europe, Asia Pacific, and RoW.

In 2013, North America estimated for the major market share around 41% on account of increasing number of targeted diseases and high spending for healthcare in this region. In addition, implementation of several regulations for monitoring the environmental pollution such as National Environmental Policy Act, Clean Water Act, and Clean Air Act in the U.S. are anticipated to create many lucrative opportunities in the market. Moreover, technological improvements such as launch of miniaturized diagnostic equipment for rapid and accurate results and increasing adoption of electronic medical records (EMR) are also expected to drive the market in this region during the forecast period.

Asia Pacific is expected to grow with highest CAGR during the forecast period due to existence of high unmet medical needs concerning targeted diseases, increasing awareness among the patients, and rise in healthcare expenditure in the region. In addition, growing demand for healthcare, point-of-care, home, and other healthcare development and increasing efforts from government to reduce hospital stays by forming outpatient care models are expected to support the market growth in this region. Additionally, the Chinese Government is making high investments on its computing infrastructure with the help of China Grid introduced by Chinese Academy of Sciences and Ministry of Education and the China National Grid (CNGrid) supported by the Ministry of Science and Technology.

Europe is expected to grow on account of increasing funding in the region. Max-Planck Institute has made high funding by collaborating with the Federal Government of Germany and several other German states. The European Molecular Biology Laboratory’s European Institute (EMBL-EBI) and BBSRC, with support by the UK Government has also commented high investments in 2012.

Prominent companies operating in the market include LifeScan, Inc.; Innovative Biosensors Inc.; EG & IC Sensors, Inc.; Pinnacle Technologies Inc.; and Strategic Diagnostics.

Access Full Press Release of this Report: www.grandviewresearch.com/press-release/global-biosensors-market

 About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Women’s Health Therapeuticss Market Is Poised To Reach USD 210.9 Billion By 2025:Key Participant Teva Pharmaceutical Industries Ltd

San Francisco, 04 October 2018, The global women’s health therapeutics market size is expected to reach USD 210.9 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 8.8% over the forecast period. Entry of effective drugs, a rise in awareness about early diagnosis and treatment, along with prevalence of chronic diseases are among the key factors likely to drive the market during the forecast period.

The women’s health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications. In October 2016, Prelude Fertility, Inc. received USD 200 million from the Reproductive Biology Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing fertility services and treatment to people with delayed childbirth. Juneau Biosciences, LLC has deployed USD 35 million until 2017 towards development of molecular diagnostics and therapeutics for endometriosis (uterus) conditions.

In January 2018, Melinta Therapeutics, Inc. acquired The Medicines Company’s infectious diseases business. This acquisition would help to the former expand its portfolio by offering life-saving treatment options. In November 2017, Biocon launched KRABEVA, a biosimilar used for the treatment of metastatic colorectal, cervical, ovarian, and brain cancer. Increasing investments by top market players are anticipated to propel the global market over the forecast period.

There is significant unmet need associated with treatment options for female sexual dysfunction. Currently, there are no Food and Drug Administration (FDA)-approved drugs for the treatment of female sexual dysfunction and many promising molecules are in late stage of development phase. Some of these molecules include LibiGel by BioSante Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II of clinical trials respectively in U.S.

Full Research Report On Women’s Health Therapeutics Market Analysis:
www.grandviewresearch.com/industry-analysis/womens-health-therapeutics-market

Further key findings from the report suggest:

·         By type, infection accounted for the largest market share in 2017 and is expected to maintain its dominance during the forecast period due to rising drug approvals, availability of diagnostic tests and treatments, and high incidence of infectious diseases

·         Ovarian cancer is anticipated to be the fastest-growing sub-segment of oncology during the forecast period due to high prevalence of ovarian cancer and approval of new and improved drugs

·         North America is expected to maintain its dominance in the coming years due to high awareness about women’s health, increase in number of advanced diagnostic and treatment methods, mergers and acquisitions by market players, and rise in infections and cancer cases

·         Asia Pacific is likely to witness significant growth over the next decade due to improving healthcare facilities, increase in commercialization and approval of products, and investment by market players

·         Some of the key players in women’s health therapeutics market are Bayer AG, Merck & Co., Pfizer, Teva Pharmaceutical Industries Ltd, AstraZeneca, Bristol-Myers Squibb (BMS) Company, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and Sanofi.

Browse More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global women’s health therapeutics market based on type and region:

Women’s Health Therapeutics Type Outlook (Revenue, USD Million, 2014 - 2025)

·         Infection

·         Pregnancy

·         Oncology

o    Cervical Cancer

o    Ovarian Cancer

o    Uterine Cancer

o    Vaginal & Vulvar Cancer

Women’s Health Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    U.K.

o    France

o    Spain

o    Italy

·         Asia Pacific

o    China

o    Japan

o    India

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-womens-health-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com